NANOBIOTIX SA - ADR (NBTX) Forecast, Price Target & Analyst Ratings

NASDAQ:NBTX • US63009J1079

Current stock price

35.12 USD
+0.5 (+1.44%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NANOBIOTIX SA - ADR (NBTX).

Forecast Snapshot

Consensus Price Target

Price Target
$35.41
+ 0.83% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 19, 2026
Period
Q2 / 2026
EPS Estimate
€1.19
Revenue Estimate
23.868M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$35.41
Upside
+ 0.83%
From current price of $35.12 to mean target of $35.41, Based on 12 analyst forecasts
Low
$24.21
Median
$32.89
High
$57.49

Price Target Revisions

1 Month
29.87%
3 Months
30.89%

Price Target Summary

12 Wall Street analysts provided a forecast for the next 12 months for NBTX. The average price target is 35.41 USD. This implies a price increase of 0.83% is expected in the next year compared to the current price of 35.12.
The average price target has been revised upward by 30.89% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NBTX Current Analyst RatingNBTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

NBTX Historical Analyst RatingsNBTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.00%
NBTX was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about NBTX.
In the previous month the buy percentage consensus was at a similar level.
NBTX was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-02GuggenheimMaintains Buy -> Buy
2026-02-06GuggenheimMaintains Buy -> Buy
2025-04-04GuggenheimMaintains Buy -> Buy
2024-08-28GuggenheimInitiate Buy
2023-12-08Leerink PartnersInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 19, 2026
Period
Q2 / 2026
EPS Estimate
€1.19
Revenue Estimate
23.868M
Revenue Q2Q
-10.40%
EPS Q2Q
1,184.91%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

NBTX is expected to report earnings on 5/19/2026. The consensus EPS estimate for the next earnings is 1.19 USD and the consensus revenue estimate is 23.87M USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
NBTX revenue by date.NBTX revenue by date.
30.058M-11.609M
-138.62%		7.843M
167.56%		51.551M
557.29%		51.529M
-0.04%		121.46M
135.71%		61.749M
-49.16%		131.81M
113.46%		302.07M
129.17%		409.05M
35.42%		598.77M
46.38%
EBITDA
YoY % growth
NBTX ebitda by date.NBTX ebitda by date.
-25.266M
44.10%		-66.771M
-164.27%		-31.123M
53.39%		-18.947M
39.12%		816K
104.31%		-339.997K
-141.67%		-43.827M
-12,790.39%		171.76M
491.91%		74.011M
-56.91%		112.08M
51.44%		N/A
EBIT
YoY % growth
NBTX ebit by date.NBTX ebit by date.
-26.779M
42.66%		-68.392M
-155.39%		-32.618M
52.31%		-8.936M
72.60%		510.612K
105.71%		9.689M
1,797.53%		-2.261M
-123.34%		53.588M
2,469.68%		192.05M
258.38%		283.03M
47.37%		465.6M
64.51%
Operating Margin
NBTX operating margin by date.NBTX operating margin by date.
-89.09%589.13%-415.89%-17.33%0.99%7.98%-3.66%40.66%63.58%69.19%77.76%
EPS
YoY % growth
NBTX eps by date.NBTX eps by date.
-1.07
24.32%		-1.43
-33.33%		-0.50
65.28%		-0.62
-24.95%		-0.44
28.57%		-0.01
97.71%		0.15
1,551.00%		2.29
1,458.65%		2.99
30.53%		3.58
19.66%		N/A

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q4 / 26
EPS
Q2Q % growth		1.19
1,184.91%		1.00
358.92%
Revenue
Q2Q % growth		23.868M
-10.40%		94.86M
1,492.95%
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		N/AN/A

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NBTX Yearly Revenue VS EstimatesNBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M
NBTX Yearly EPS VS EstimatesNBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
25.56%
EPS Next 5 Year
45.91%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
37.36%
Revenue Next 5 Year
22.97%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
23.66%
EBIT Next 5 Year
124.47%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NANOBIOTIX SA - ADR / NBTX Forecast FAQ

What is the average price target for NANOBIOTIX SA - ADR (NBTX) stock?

12 analysts have analysed NBTX and the average price target is 35.41 USD. This implies a price increase of 0.83% is expected in the next year compared to the current price of 35.12.

Can you provide the upcoming earnings date for NANOBIOTIX SA - ADR?

NANOBIOTIX SA - ADR (NBTX) will report earnings on 2026-05-19.

What are the consensus estimates for NBTX stock next earnings?

The consensus EPS estimate for the next earnings of NANOBIOTIX SA - ADR (NBTX) is 1.19 USD and the consensus revenue estimate is 23.87M USD.

What is the consensus rating for NBTX stock?

The consensus rating for NANOBIOTIX SA - ADR (NBTX) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.